US 11,726,090 B2
Means and methods for diagnosing pancreatic cancer
Christoph Schröder, Heidelberg (DE); Jörg Hoheisel, Wiesloch (DE); and Tatjana Crnogorac-Jurcevic, Chislehurst (GB)
Assigned to DEUTSCHES KREBSFORSCHUNGSZENTRUM, Heidelberg (DE); and QUEEN MARY UNIVERSITY OF LONDON, London (GB)
Filed by Deutsches Krebsforschungszentrum, Heidelberg (DE); and Queen Mary University of London, London (GB)
Filed on Dec. 21, 2016, as Appl. No. 15/387,233.
Application 15/387,233 is a division of application No. 13/576,912, granted, now 9,551,035, previously published as PCT/EP2011/052182, filed on Feb. 15, 2011.
Claims priority of application No. 10001596 (EP), filed on Feb. 17, 2010.
Prior Publication US 2017/0168062 A1, Jun. 15, 2017
Int. Cl. G01N 33/574 (2006.01); C12Q 1/6886 (2018.01); G01N 33/53 (2006.01)
CPC G01N 33/57438 (2013.01) [C12Q 1/6886 (2013.01); G01N 33/5302 (2013.01); C12Q 2600/158 (2013.01)] 16 Claims
 
1. A method of treating pancreatic cancer in a subject comprising the steps of:
(a) determining in a sample of a subject suspected to suffer from pancreas cancer the amount of at least three polypeptide biomarkers selected from TMM54, MK12, MELPH, UN93B, COXAM, RASF1, AKTIP, CASPA, CDN2B, CLD7, DCOR, EWS, FAK1, GPX4, HMGB2, IGF1A, IRS2, K2C8, LYAM1, MAD4, MMP1, MMP7, S10A6, SORL, and TNR6, wherein the sample is a blood, plasma, serum, or urine sample, wherein the amount is determined with an immunoassay, wherein the immunoassay comprises:
(i) contacting the sample with an antibody microarray comprising antibodies that recognize the at least three polypeptide biomarkers, and
(ii) measuring the amounts of bound biomarkers and thereby determining the amounts of the biomarkers present in the sample;
(b) comparing the amount of the at least three biomarkers with a reference to determine if the subject suffers from pancreas cancer, wherein a decrease in the amount of AKTIP, CASPA, CDN2B, CLD7, IRS2, LYAM1, SORL, COXAM, EWS, FAK1, IGF1A, K2C8, MAD4, MELPH, MK12, MMP1, MMP7, S10A6, TMM54, TNR6, and UN93B compared to the reference is indicative of pancreatic cancer, and/or an increase in the amount of DCOR, GPX4, HMGB2, or RASF1 as compared to the reference is indicative of pancreatic cancer; and
(c) treating the subject with a pancreas cancer therapy if the subject is determined to suffer from pancreas cancer.